Traditionally, the most commonly used method of prostate cancer imaging is the CT scan or bone scan. The new use of PSMA PET-CT proved to be substantially more likely to detect metastatic tumors in men with prostate cancer than the standard imaging approach. The FDA hasn’t approached any PSMA-targeted imaging agents, so PSMA PET-CT isn’t available in the US outside of clinical studies yet.
For more information: https://www.cancer.gov/news-events/cancer-currents-blog/2020/prostate-cancer-psma-pet-ct-metastasis
